GCT appoints Monika Sarmirova as its Country Manager for operations in Slovakia and the Czech Republic.

As the company strengthened its experience in the region within the past several years, adding a senior local team member to help oversee an increasing number of ongoing studies is the next step necessary to meet the demand without compromising quality. We are happy to welcome the new country manager for operations in Slovakia and the Czech Republic and to continue creating research that impacts patients and society together.

We are pleased to have Monika on board. Her in-depth local experience, knowledge of the clinical trial industry, and managerial skills will complement our growing team of seasoned executives.”
— Dr. Eugene Selivra, CEO

Monika Sarmirova brings to GCT 13 years of experience working in pharmaceutical and biotech companies, as well as contract research organizations (CROs). Mrs. Sarmirova has experience with trials of pharmaceuticals and GMO medicinal products. Having worked at one of the global pharmaceutical companies recently, she headed a countrywide pharmacovigilance team and was responsible for GCP/GVP compliance.

“I am thrilled that Slovakia and Czechia are becoming even more attractive countries for clinical trials sponsored by companies from all over the globe. I hope that we will be able to work towards better patient care and new treatment options by delivering outstanding services for our clients”, said Monika.

Slovakia is one of the most developed health device and pharmaceutical markets in the Central-Eastern European region. Slovakia’s medical device manufacturing sector has a long history, particularly in the area of orthopedic and dental equipment. At present, Slovak companies largely produce single-use medical equipment. Domestic medical device production is estimated to exceed $300 million.

As for the Czech Republic, the pharmaceutical industry there is one of the key manufacturing sectors with around 2,5 billion worth of government funds over the past ten years. The Czech Republic has a solid clinical research infrastructure and a supportive regulatory environment with over 250 hospitals (including university hospitals), 100 clinics and other healthcare institutions, both public and private. The Czech universal healthcare system is favorable to patient enrolment in clinical trials in every possible way.
GCT is conducting clinical trials in both countries since 2016. This expansion allows the company to bring on new studies, staff, to strengthen the connection with the local KOLs and experienced hospitals, and eventually access and include more patients in our studies.

Full press release published on EinPressWire